PRE

ANALYST NOTE: PRE (Prenetics Global Limited) Date: 2026-08-28 Status: Actionable / Coil Confirmed

1. Structural Readiness

As of the close on 2026-08-28, PRE exhibits a confirmed coil breakout. The setup is currently actionable.

• Conservative Entry: $23.25
• Current Price: $26.25
• Extension: +12.9% above conservative entry.
• Volatility Context: The ATR at the time of the breakout was 7.6% (Very High), and the current ATR stands at 7.1% (Very High). This elevated volatility profile suggests a structural quality in the move, though it necessitates careful position sizing relative to the historical "sweet spot" of 4–6%.
• Setup Status: The coil is confirmed. The price has cleared the consolidation base, and the setup is not merely forming; the breakout signal has fired. There is no evidence of a setup violation or invalidation; the structure is active and positive.

2. The Thesis Layer

At this date, PRE is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup in the current evidence base. The investment case is not derived from a macro secular trend (e.g., "the AI revolution" or "demographic shift") but is instead driven by the convergence of a confirmed technical breakout and a distinct inflection in the company's fundamental business metrics. The conviction must be weighed strictly on the quality of the setup and the immediate business fundamentals, without inventing a broader narrative.

3. The Business

Prenetics Global Limited operates as a hybrid health technology and consumer wellness company. Its business model has evolved from a pure-play genomic testing provider (CircleDNA) to a diversified entity including a direct-to-consumer (DTC) supplement brand (IM8).

Key Business Metrics & Operations (as of Q2 2026 Earnings, 2026-08-18):

• Revenue Scale: The company reported Q2 2026 revenue of $46.5 million, representing a 29% sequential increase and a 3.9x year-over-year growth.
• Run Rate: July 2026 was the strongest month in company history, generating $20.9 million in revenue, implying an annualized run rate of approximately $251 million.
• Cash Flow Inflection: Management stated that consolidated adjusted free cash flow turned positive for the first time in the company's history in July 2026, driven by the funding under the "Countless" facility.
• Customer Economics: The company acquired a record cohort in the recent period with a Customer Acquisition Cost (CAC) of $239, a 21% reduction from Q2. Management claims every acquisition dollar generates $1.52 of gross profit over the customer lifecycle.
• Product Pipeline: Management expects to launch "IM8 hydration" in Q4 2026 into a $37 billion market, followed by a premium gummy line in Q1 2027 into a $25 billion category.
• Guidance: Management has initiated 2027 figures, projecting $400 million or more in revenue.

Risk Factors (per 2026-04-30 SEC Filing):

• New Market Uncertainty: Expansion into consumer health and wellness (IM8) introduces risks regarding product safety, efficacy, and regulatory compliance.
• Marketing Dependency: The company relies heavily on digital advertising platforms (Google, Facebook), which may terminate agreements. Selling and marketing expenses represented 38.5% of revenue in FY 2025 ($35.5 million), a ratio management anticipates will remain significant.
• Historical Losses: The company reported net losses of $38.7 million for the fiscal year ended December 31, 2025, following losses of $64.8 million in 2023 and $49.8 million in 2024.
• Treasury Strategy: Between June and December 2025, the company pursued a digital asset treasury strategy, acquiring approximately 510 Bitcoin.

4. Archetype and Conviction

Archetype: Growth Leader. Fit: The name fits the "Growth Leader" archetype due to the explosive sequential revenue growth (29% QoQ), the successful pivot to a high-margin DTC supplement model (IM8), and the recent achievement of positive free cash flow. The business is demonstrating the ability to scale marketing spend efficiently (lowering CAC) while expanding revenue run rates.

Conviction Stack:

• Thesis Strength: Moderate. The lack of a named secular thesis limits the "story" to the company's specific execution, but the execution metrics are strong.
• Evidence Quality: High. The earnings transcript provides precise, quantified data on cash flow, CAC, and revenue run rates.
• Structural Quality: High. The confirmed coil breakout with a very high ATR (7.6%) indicates strong institutional interest and momentum.
• Rerating Potential: Significant. The transition from a loss-making genomic tester to a cash-flow-positive consumer health brand with a $400M+ 2027 guidance creates a potential multiple expansion opportunity, provided the market accepts the new business model.

5. Invalidations, Strengtheners, and Gaps

What Would Strengthen the Case:

• Continued positive consolidated adjusted free cash flow in Q3 2026 (as guided).
• Successful launch and early traction of the IM8 hydration product in Q4 2026.
• Sustained reduction in CAC or improvement in gross profit per acquisition dollar.
• Continued insider buying (management has already purchased $1.0M in August 2026).

What Would Invalidate the Case:

• A return to negative consolidated adjusted free cash flow in Q3 2026.
• Significant churn in the IM8 subscriber base or failure to meet the $220–230 million FY 2026 IM8 revenue guidance.
• Termination of major digital advertising partnerships (Google/Facebook) leading to a spike in CAC.
• A breach of the current price structure (though we do not use "invalidation" language for stops, a sustained close below the breakout base would negate the setup).

Gaps in Evidence:

• Long-term Retention Data: While CAC and gross profit per lifecycle are cited, specific data on customer retention rates (LTV) beyond the "lifecycle" aggregate is not detailed in the provided evidence.
• Regulatory Specifics: The SEC filing notes risks regarding "safe and effective" products, but specific regulatory hurdles or approval timelines for the new hydration/gummy lines are not quantified in the current evidence.
• Bitcoin Exposure Impact: The impact of the 510 Bitcoin holding on the balance sheet volatility and liquidity is noted but not quantified in the Q2 earnings context.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Q2 revenue up 29% sequentially to $46.5M with July hitting a record $20.9M; First-ever positive consolidated adjusted free cash flow in July 2026; Confirmed coil breakout with +12.9% extension and very high ATR. Key risks: High marketing expense ratio (38.5% of revenue) and dependency on third-party ad platforms; Historical net losses and the inherent risk of scaling a new consumer health brand (IM8); Volatility from Bitcoin treasury strategy. Rating boundary: This is rated Buy rather than Strong Buy because the company is still in a transition phase from a loss-making genomic tester to a profitable consumer brand, and the "very high" ATR (7.1%) suggests elevated volatility that warrants a measured position size rather than maximum conviction. It is not a Hold because the fundamental inflection (positive FCF) and technical setup (confirmed coil) are both present and aligned. Sizing hint: Position size should be calibrated to the very high ATR (7.1%) to account for wider price swings, likely smaller than a standard high-conviction growth setup. Expected path: Management expects positive FCF to continue through Q3 2026; the company will likely focus on scaling IM8 hydration and gummy launches in late 2026 to drive toward the $400M+ 2027 guidance. Expected horizon: 6 to 12 months for the new product lines to fully integrate into the revenue mix and for the market to price in the sustained profitability. Failure mode to watch: A return to negative free cash flow in Q3 2026 or a failure to meet the raised FY 2026 IM8 revenue guidance of $220–230 million.